Quote | Kiora Pharmaceuticals Inc. (NASDAQ:KPRX)
Last: | $5.36 |
---|---|
Change Percent: | -2.27% |
Open: | $4.95 |
Close: | $5.36 |
High: | $5.55 |
Low: | $4.7 |
Volume: | 122,929 |
Last Trade Date Time: | 06/14/2024 03:00:00 am |
News | Kiora Pharmaceuticals Inc. (NASDAQ:KPRX)
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
Encinitas, California--(Newsfile Corp. - May 20, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming investor conferences that will be available to investors live with the replay available on-demand. On Wednesday May 22, at 3:00...
Message Board Posts | Kiora Pharmaceuticals Inc. (NASDAQ:KPRX)
Subject | By | Source | When |
---|---|---|---|
Was a good trade yesterday wait for $5.28 | tw0122 | investorshub | 02/10/2023 1:14:25 PM |
One more run $11 to $13 zone on | tw0122 | investorshub | 02/09/2023 3:18:17 PM |
znewcar1: $KPRX 52% v36,1M c6.94 f1,796M H8.515 ML3.21 RL4.36 | znewcar1 | investorshangout | 02/08/2023 10:19:35 PM |
All doubt aside i hope it runs to | PennyPusher786 | investorshub | 02/08/2023 7:27:10 PM |
Bait and rug pull coming... institutions run share | PennyPusher786 | investorshub | 02/08/2023 7:26:45 PM |
News, Short Squeeze, Breakout and More Instantly...
Kiora Pharmaceuticals Inc. Company Name:
KPRX Stock Symbol:
NASDAQ Market:
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
Encinitas, California--(Newsfile Corp. - May 20, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming investor conferences that will be available to investors live with the replay available on-demand. On Wednesday May 22, at 3:00...
Phase 2 trial for KIO-301 for the treatment of retinitis pigmentosa, in partnership with Théa Open Innovation, expected to be initiated in Q4 2024 Phase 2 clinical trial for KIO-104 for retinal inflammation expected to begin in 2025 Ended Q1 2024 with $31.3 million in cash and cash eq...